Maia Biotechnology Inc (MAIA)

MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University

Georgia’s only National Cancer Institute (NCI)-designated Comprehensive Cancer Center; well recognized at the...

MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial

Additional data from MAIA’s THIO-101 expansion may further support an accelerated approval filing with the FDA...

MAIA Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial

MAIA’s novel telomere-targeting therapy being evaluated as a third-line treatment for advanced non-small cell...

MAIA Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 THIO-101 Trial Expansion

Additional data from THIO-101 trial expansion studies may further support a potential Accelerated Approval...

MAIA Biotechnology Announces Open Market Purchases by CEO and Director

CHICAGO, June 02, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

MAIA Biotechnology Presents Trial in Progress Poster for Pivotal Phase 3 Clinical Trial of Novel Telomere Targeting Agent at 2026 Annual Meeting of American Society of Clinical Oncology

CHICAGO, June 01, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the...

Form 8-K - Current report

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form 8-K - Current report